文献速递慢性肾脏病肾血管病与高血压

巴卓司他治疗慢性肾脏病合并未控制高血压参与者的疗效与安全性:一项随机双盲安慰剂对照试验

Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.
PubMed 文献 · J Am Soc Nephrol · 2025-09-06

这项2期随机双盲安慰剂对照多中心试验纳入195例接受ACEI或ARB治疗、诊室收缩压≥140 mmHg(无糖尿病)或≥130 mmHg(合并2型糖尿病)且尿白蛋白肌酐比≥100 mg/g的CKD合并未控制高血压参与者,随机接受巴卓司他低剂量、高剂量或安慰剂治疗26周。巴卓司他汇总组安慰剂校正的收缩压变化为–8.1(95%CI –13.4至–2.8)mmHg,P=0.003;高钾血症是最常见的治疗中出现的不良事件。

要点

  • 巴卓司他汇总组第26周安慰剂校正收缩压变化为–8.1(95%CI –13.4至–2.8)mmHg,P=0.003。
  • 低剂量组收缩压变化为–9.0(95%CI –15.1至–2.9)mmHg,P=0.004;高剂量组为–7.2(95%CI –13.2至–1.2)mmHg,P=0.02。
  • 高钾血症作为不良事件在巴卓司他汇总组报告41%(53/128),安慰剂组5%(3/64)。

核心结论

  • 巴卓司他降低了CKD合并未控制高血压参与者的收缩压,高钾血症作为不良事件较安慰剂更常见。

研究设计与样本

  • 2期随机双盲安慰剂对照多中心试验(NCT05432167),纳入195例接受ACEI或ARB治疗且诊室收缩压≥140 mmHg(无糖尿病)或≥130 mmHg(合并2型糖尿病)、尿白蛋白肌酐比≥100 mg/g的参与者。
  • 参与者按1:1:1随机接受巴卓司他低剂量(0.5 mg上调至1 mg)、高剂量(2 mg上调至4 mg)或安慰剂治疗26周。
  • 主要终点为第26周巴卓司他汇总治疗组与安慰剂组相比诊室收缩压较基线的变化;次要终点按高剂量或低剂量评估该变化,终点按层级顺序检验。

主要发现

  • 2022年4月29日至2024年5月2日期间随机化195例参与者,平均(SD)年龄66(11)岁,女性32%,白人113例(58%),80%合并2型糖尿病。
  • 平均(SD)基线收缩压151.2(13.1)mmHg,平均(SD)基线eGFR 44(14)ml/min/1.73 m²,中位(Q1,Q3)尿白蛋白肌酐比714(307,1429)mg/g。
  • 巴卓司他汇总组第26周安慰剂校正收缩压变化为–8.1(95%CI –13.4至–2.8;P=0.003)mmHg;低剂量组–9.0(–15.1至–2.9;P=0.004)mmHg;高剂量组–7.2(–13.2至–1.2;P=0.02)mmHg。
  • 高钾血症作为不良事件在巴卓司他汇总组报告41%(53/128),安慰剂组5%(3/64)。

关键数值与推荐

  • 巴卓司他汇总组第26周安慰剂校正收缩压变化为–8.1(95%CI –13.4至–2.8)mmHg,P=0.003。
  • 低剂量组第26周安慰剂校正收缩压变化为–9.0(95%CI –15.1至–2.9)mmHg,P=0.004;高剂量组为–7.2(95%CI –13.2至–1.2)mmHg,P=0.02。
  • 高钾血症作为不良事件在巴卓司他汇总组报告41%(53/128),安慰剂组5%(3/64)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: This phase 2 trial assessed baxdrostat, an aldosterone synthase inhibitor, in participants with CKD and uncontrolled hypertension. Baxdrostat showed placebo-corrected reduction in systolic BP of –8.1 (95% confidence interval, –13.4 to –2.8) mm Hg, P = 0.003. Baxdrostat was well tolerated; hyperkalemia was the most frequent treatment-emergent adverse event. BACKGROUND: Aldosterone increases BP and contributes to CKD progression. We evaluated the efficacy and safety of baxdrostat, an aldosterone synthase inhibitor, in participants with CKD and uncontrolled hypertension. METHODS: This was a phase 2, randomized, double-blind, placebo-controlled, multicenter trial (NCT05432167). Eligible participants were treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and had a mean seated office systolic BP ≥140 mm Hg (without diabetes) or ≥130 mm Hg (with type 2 diabetes) and a urine albumin-creatinine ratio of≥100 mg/g. Participants were randomized (1:1:1) to baxdrostat low-dose (0.5 mg up-titrated to 1 mg), high-dose (2 mg up-titrated to 4 mg), or placebo for 26 weeks. The primary end point was change from baseline in mean seated office systolic BP at week 26 in the baxdrostat pooled treatment group versus placebo. The secondary end point assessed this change by high-dose or low-dose baxdrostat; end points were tested sequentially in a hierarchal manner. RESULTS: Between April 29, 2022, and May 2, 2024, 195 participants were randomized. The mean (SD) age was 66 (11) years, 32% were women, 113 (58%) were White, and 80% had type 2 diabetes. The mean (SD) baseline systolic BP was 151.2 (13.1) mm Hg; the mean (SD) baseline eGFR was 44 (14) ml/min per 1.73 m2, and the median (Q1, Q3) urine albumin-creatinine ratio was 714 (307, 1429) mg/g. The mean placebo-corrected change in systolic BP from baseline to week 26 for the baxdrostat pooled group was –8.1 (95% confidence interval, −13.4 to −2.8; P = 0.003) mm Hg; low-dose −9.0 (−15.1 to −2.9; P = 0.004) mm Hg; high-dose −7.2 (−13.2 to −1.2; P = 0.02) mm Hg. Hyperkalemia was recorded as an adverse event in 41% (53/128) of participants in the baxdrostat pooled group and 5% (3/64) in the placebo group. CONCLUSIONS: Baxdrostat reduced systolic BP in participants with CKD and uncontrolled hypertension. Hyperkalemia was reported more commonly as an adverse event with baxdrostat versus placebo. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: NCT05432167.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Dwyer JP, Maklad N, Vedin O, et al. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2025. PMID: 40913594. doi:10.1681/ASN.0000000849

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。